Every Benefit on the Standard Amanita List Is a Measurement That Rises on Its Own
The usual list runs something like this: improved mood and emotional balance, enhanced creativity, reduced anxiety and mental chatter, better sleep quality. Look at what those four have in common before you look at the mushroom. Every one is self-rated. Every one fluctuates naturally from week to week. And every one is typically measured starting from the moment somebody decided things were bad enough to try something. That combination has a name in epidemiology, it has been formally described since at least 2005, and it produces apparent improvement in the complete absence of any active ingredient. It isn't the placebo effect. It's regression to the mean, and this benefit list is a textbook case of the conditions that generate it.
What Regression to the Mean Actually Is
The canonical description is short: regression to the mean is "a statistical phenomenon that can make natural variation in repeated data look like real change. It happens when unusually large or small measurements tend to be followed by measurements that are closer to the mean" (Barnett, van der Pols & Dobson, International Journal of Epidemiology 34(1):215–220, 2005).
Nothing mystical is happening. If a quantity bounces around an average, and you happen to measure it on an unusually bad day, the next measurement will probably be less bad — because most days aren't unusually bad. Take anything on that day and the improvement gets attributed to the thing you took. The authors are blunt about how often this goes unnoticed: RTM is "a ubiquitous phenomenon in repeated data and should always be considered as a possible cause of an observed change."
Both of the Conditions That Amplify It Are Present Here
Barnett and colleagues specify exactly when the effect gets worse: "The effect of RTM in a sample becomes more noticeable with increasing measurement error and when follow-up measurements are only examined on a sub-sample selected using a baseline value."
Amanita microdosing satisfies both, and not marginally.
Selection on a baseline value. Nobody begins a microdosing regimen on an average Tuesday when their mood, sleep and focus are all sitting at their personal norm. People start when something feels off — that's what makes it worth trying. The sample generating the testimony is therefore selected precisely on a low baseline reading of the very variables it goes on to track.
Measurement error. The outcomes are "how's my mood," "how anxious do I feel," "did I sleep well," rated informally, often in a journal, by the same person who chose the intervention and is paying attention to it for the first time. That is a high-error measurement in the technical sense, which is exactly the condition that makes RTM more visible.
This Is Not the Placebo Effect — and the Difference Matters
The two get conflated constantly, and keeping them apart is the whole point of this article. A placebo response requires a person: an expectation, a belief, a hopeful interpretation. Regression to the mean requires nothing at all. It would occur if you tracked the same numbers in an empty room. Put a thermometer outside on an unseasonably cold morning and the following week will probably be milder; the thermometer has no expectations.
The practical upshot is that "I know it's not just placebo, I really did feel different" doesn't address this objection, because RTM doesn't operate through feeling. Both effects can run simultaneously, and typically do. We covered the expectancy half — where intention-setting turns out to predict the reported outcome — in our piece on what "self-discovery" actually measures. This is the other half, and it's the one that survives even total scepticism on the user's part.
What the Benefit List Conspicuously Doesn't Contain
Here's the tell. Scan any Amanita benefit list and notice what's absent: reaction time, a scored memory test, grip strength, a timed task, anything measured by an instrument rather than an impression.
That absence isn't an accident of marketing style. Objective measures resist RTM in ways subjective ones don't — they have lower measurement error, they can be baselined over multiple sessions before any intervention, and they produce a number you can't unconsciously nudge. A benefit list made of stopwatch outcomes would be falsifiable. A benefit list made of mood, calm, creativity and sleep quality is a set of variables uniquely positioned to improve on their own and uniquely difficult to check. Whether or not anyone chose it deliberately, it's the least testable possible list.
What Happens When Somebody Adds a Control Condition
This isn't theoretical. The strongest test in microdosing research had 191 people run their own placebo control by mixing placebo and microdose capsules and losing track of which was which. All psychological outcomes improved from baseline. So did the placebo group's. No significant difference emerged between the arms (Szigeti et al., eLife, 2021).
That result is precisely what RTM plus expectancy predicts together: real improvement from baseline in everybody, no separation between the substance and the blank. It's also worth being clear that this was psilocybin and LSD, not Amanita — Amanita has zero registered clinical studies of any kind (ClinicalTrials.gov, checked 14 August 2026), so the corresponding test has never been run here. The broader picture from controlled work is covered in our piece on what the controlled studies actually found.
The Exposure Isn't Measured Either
There's a second problem sitting underneath the first. Even if the outcomes were solid, the input isn't known.
A survey of 1,116 microdosers found that while people reported detailed schedules and motivations — performance enhancement was the leading motive at 37% — "the majority of users, however, were oblivious about the consumed dose" (Hutten et al., International Journal of Neuropsychopharmacology 22:426–434). That was for substances that come in reasonably standardised units. Amanita has no such units: there are no widely recognised testing standards for retail products, and published figures "do not establish a reliable dose–response relationship" (Ordak, Frontiers in Pharmacology, 2026). Drying converts ibotenic acid to muscimol at an uncontrolled rate, so equal weights aren't equal doses — which is why we argue grams are the wrong unit.
So the benefit claim rests on an unmeasured exposure producing an unstable outcome in a sample selected at its low point. Each of those problems alone would be enough to withhold judgement.
How You Would Actually Tell the Difference
The corrections are known, and they're the same ones Barnett and colleagues recommend at the design stage. Baseline properly: track the outcome for several weeks before changing anything, so you know your normal range and your normal variability rather than one bad reading. Use the same measure each time rather than an impression. And include a control condition — the self-blinding capsule method above is the amateur-accessible version, and it exists precisely because personal testimony can't separate these effects.
Applied honestly, most people find their "bad week" wasn't outside their ordinary range. That's not a reason to feel foolish; it's what the statistics predict for everybody, including the people who designed the studies. Amanita muscaria isn't an approved treatment for low mood, anxiety, insomnia or anything else, and none of the mechanism arguments change the measurement problem described here. Our piece on which claimed benefits are even pharmacologically plausible takes the mechanism side one claim at a time.
The Bottom Line
Ask what a benefit list is made of before asking whether the substance works. This one is made of four self-rated, naturally fluctuating states, tracked by people who started measuring on a bad week, with an unmeasured dose and no control condition. Regression to the mean predicts improvement under exactly those conditions with no active ingredient involved, and it's a separate phenomenon from placebo — it doesn't need you to believe anything. That doesn't prove Amanita does nothing. It means the standard evidence offered can't distinguish "it worked" from "the week was always going to be better," and until somebody runs the comparison, neither can you.
Nothing here is medical advice. If mood, anxiety or sleep are the reason you're looking, those are worth raising with a clinician, and if you take sedatives, sleep medication or anti-anxiety medication, speak to one before considering any GABA-A active substance — see our practical guide to mindful use.
Frequently Asked Questions
What is regression to the mean in plain terms?
It's the tendency for unusually high or low measurements to be followed by ones closer to average. Because it makes natural variation in repeated data look like real change, any improvement measured from an unusually bad starting point is partly or wholly explained by it, regardless of what you did in between.
Isn't that just the placebo effect?
No, and the distinction is important. A placebo response works through expectation and belief. Regression to the mean is purely statistical and needs no participant at all — it would show up in weather data. Both usually operate at once, which is why "it wasn't just placebo, I genuinely felt different" doesn't settle the question.
Why do these four benefits in particular get claimed?
Because mood, anxiety, creativity and sleep quality are all self-rated and naturally variable, which makes them the outcomes most susceptible to the effect. Notably absent from such lists is any objective measure — a timed task or a scored test — which would have lower measurement error and would be much harder to shift.
What did the self-blinding study show?
That improvement appeared in both arms. Among 191 participants who mixed their own placebo and microdose capsules, all psychological outcomes improved from baseline — but so did the placebo group's, with no significant difference between groups. That's the pattern regression to the mean and expectancy jointly predict.
Has this been tested with Amanita muscaria specifically?
No. A ClinicalTrials.gov search on 14 August 2026 returned zero registered studies for "Amanita muscaria" or "fly agaric", so no controlled comparison exists. The published literature is described as limited predominantly to case reports.
Do microdosers know how much they're taking?
Frequently not. In a survey of 1,116 microdosers, the majority were reported to be unaware of the dose they consumed — and that was with substances that come in more standardised units than dried mushroom material. Amanita has no recognised testing standards, and drying changes the ibotenic-acid-to-muscimol ratio unpredictably.
How could I test this for myself more honestly?
Baseline first — track the outcome for several weeks before changing anything, so you know your ordinary range rather than one bad reading. Use the same measure every time instead of a general impression. And build in a control condition, such as the self-blinding capsule method, since personal experience alone can't separate a real effect from a returning average.
Written by Viktor, Amanita Store. We sell dried Amanita muscaria caps and tincture as wellness and collector items, not as treatments — which is why this page examines how the benefit list was measured rather than repeating it.